NRIX Q3 2025 Earnings
Reported Oct 9, 2025 at 4:02 PM ET · SEC Source
Q3 25 EPS
$-1.03
MISS 21.08%
Est. $-0.85
Q3 25 Revenue
$7.9M
MISS 50.85%
Est. $16.1M
vs S&P Since Q3 25
+76.2%
BEATING MARKET
NRIX +88.5% vs S&P +12.3%
Market Reaction
Did NRIX Beat Earnings? Q3 2025 Results
Nurix Therapeutics delivered a sharply disappointing fiscal third quarter, missing on both the top and bottom lines as the clinical-stage biotech ramped spending ahead of pivotal trials for its lead drug candidate bexobrutideg. Revenue fell 37.3% yea… Read more Nurix Therapeutics delivered a sharply disappointing fiscal third quarter, missing on both the top and bottom lines as the clinical-stage biotech ramped spending ahead of pivotal trials for its lead drug candidate bexobrutideg. Revenue fell 37.3% year over year to $7.89 million, well short of the $16.06 million consensus and reflecting a 50.85% miss, as collaboration income from Sanofi declined following the end of an initial research term for certain drug targets. The wider-than-expected net loss drove earnings per share to a loss of $1.03, missing the $-0.85 consensus estimate by 21.08%, with R&D expenses surging to $86.12 million from $55.48 million a year ago as the company accelerated clinical enrollment and manufacturing tied to bexobrutideg. Analysts subsequently trimmed price targets, though buy-side sentiment remained broadly constructive given the drug's 80.9% overall response rate in relapsed and refractory CLL patients. Nurix closed the quarter with $428.83 million in cash and marketable securities and plans to initiate pivotal CLL trials in the second half of 2025.
Key Takeaways
- • Accelerated enrollment and clinical trial expansion for bexobrutideg driving increased R&D spend
- • Lower Sanofi collaboration revenue as initial research term for certain drug targets ended
- • Higher percentage of completion of Pfizer collaboration performance obligations partially offset revenue decline
NRIX YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
NRIX Revenue by Segment
With YoY comparisons, source: SEC Filings
“Nurix is preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL patients in the fourth quarter of 2025 and we have outlined our plans for potential accelerated approval with a single arm study as well as a confirmatory randomized control Phase 3 study for full approval.”
— Arthur T. Sands, Q3 2025 Earnings Press Release
NRIX Earnings Trends
NRIX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NRIX EPS Trend
Earnings per share: estimate vs actual
NRIX Revenue Trend
Quarterly revenue: estimate vs actual
NRIX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.76 | $-0.79 | -3.32% | $6.3M | -56.09% |
| Q4 25 BEAT FY | $-0.92 | $-0.82 | +10.85% | $13.6M | +1.22% |
| FY Full Year | — | $-3.05 | — | $84.0M | — |
| Q3 25 MISS | $-0.85 | $-1.03 | -21.08% | $7.9M | -50.85% |
| Q2 25 BEAT | $-0.74 | $-0.52 | +30.15% | $44.1M | +151.56% |